Trial Outcomes & Findings for The Effects of Videogames on Depression Symptoms and Brain Dynamics (NCT NCT05426265)

NCT ID: NCT05426265

Last Updated: 2026-04-29

Results Overview

The patient health questionnaire (PHQ-9, Kroenke et al., 2001) is a self-report measure of major depressive disorder. The PHQ-9 scores each of the nine DSM-IV criteria for MDD from "0" (not at all) to "3" (nearly every day), providing a 0-27 severity score of depression. The higher the total score the more severe the depression. The change in the PHQ-9 total score between before the 12 week intervention and after the intervention is measured. The change score of MEL-T01 group is compared with the change score of the treatment-as-usual (TAU) group.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

1001 participants

Primary outcome timeframe

Day 0 to Day 84

Results posted on

2026-04-29

Participant Flow

Patients were recruited between 28th of June 2022 and 31st of December 2023. The study was conducted remotely in Finland.

1,384 participants were assessed for eligibility and 1,001 were enrolled and randomized to MEL-T01, MEL-S01, or TAU. Participants randomized to TAU were further allocated at baseline to receive either MEL-T01 or MEL-S01 after the initial 12-week period.

Participant milestones

Participant milestones
Measure
MEL-T01
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01 as adjunct to TAU.
MEL-S01
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01 as adjunct to TAU.
TAU (Treatment-As-Usual; First TAU, Then MEL-T01)
Treatment-as-usual in healthcare for 12 weeks. Then, the participant is given acess to MEL-T01 for 12 weeks.
TAU (Treatment-As-Usual; First TAU, Then MEL-S01)
Treatment-as-usual in healthcare for 12 weeks. Then, the participant is given acess to MEL-T01 for 12 weeks.
Overall Study
STARTED
337
347
153
164
Overall Study
COMPLETED
99
96
138
150
Overall Study
NOT COMPLETED
238
251
15
14

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=96 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
n=288 Participants
Treatment-as-usual in healthcare.
Total
n=483 Participants
Total of all reporting groups
Age, Continuous
33.2 years
STANDARD_DEVIATION 8.9 • n=99 Participants
35.2 years
STANDARD_DEVIATION 10.4 • n=96 Participants
33.5 years
STANDARD_DEVIATION 9.4 • n=288 Participants
33.8 years
STANDARD_DEVIATION 9.5 • n=483 Participants
Sex/Gender, Customized
Woman
65 Participants
n=99 Participants
62 Participants
n=96 Participants
188 Participants
n=288 Participants
315 Participants
n=483 Participants
Sex/Gender, Customized
Man
24 Participants
n=99 Participants
25 Participants
n=96 Participants
72 Participants
n=288 Participants
121 Participants
n=483 Participants
Sex/Gender, Customized
Other
10 Participants
n=99 Participants
9 Participants
n=96 Participants
28 Participants
n=288 Participants
47 Participants
n=483 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
Finland
99 participants
n=99 Participants
96 participants
n=96 Participants
288 participants
n=288 Participants
483 participants
n=483 Participants
PHQ-9
15.4 units on a scale
STANDARD_DEVIATION 4.4 • n=99 Participants
15.3 units on a scale
STANDARD_DEVIATION 4.5 • n=96 Participants
15.0 units on a scale
STANDARD_DEVIATION 4.8 • n=288 Participants
15.1 units on a scale
STANDARD_DEVIATION 4.7 • n=483 Participants

PRIMARY outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12; TAU participants were pooled as all received identical treatment during this period, regardless of later allocation.

The patient health questionnaire (PHQ-9, Kroenke et al., 2001) is a self-report measure of major depressive disorder. The PHQ-9 scores each of the nine DSM-IV criteria for MDD from "0" (not at all) to "3" (nearly every day), providing a 0-27 severity score of depression. The higher the total score the more severe the depression. The change in the PHQ-9 total score between before the 12 week intervention and after the intervention is measured. The change score of MEL-T01 group is compared with the change score of the treatment-as-usual (TAU) group.

Outcome measures

Outcome measures
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=288 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
PHQ-9 Total Change From Baseline to Posttreatment: Experimental Group vs. Treatment as Usual Group
-1.941 adjusted score change
Interval -2.288 to -1.594
-0.803 adjusted score change
Interval -1.006 to -0.599

PRIMARY outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12; TAU participants were pooled as all received identical treatment during this period, regardless of later allocation.

The patient health questionnaire (PHQ-9, Kroenke et al., 2001) is a self-report measure of major depressive disorder. The PHQ-9 scores each of the nine DSM-IV criteria for MDD from "0" (not at all) to "3" (nearly every day), providing a 0-27 severity score of depression. The higher the total score the more severe the depression. The change in the PHQ-9 total score between before the 12 week intervention and after the intervention is measured. The change score of MEL-S01 group is compared with the change score of the treatment-as-usual (TAU) group.

Outcome measures

Outcome measures
Measure
MEL-T01
n=96 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=288 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
PHQ-9 Total Change From Baseline to Posttreatment: Active Comparator Group vs. Treatment as Usual Group
-1.429 adjusted score change
Interval -1.781 to -1.076
-0.803 adjusted score change
Interval -1.006 to -0.599

PRIMARY outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12.

The patient health questionnaire (PHQ-9, Kroenke et al., 2001) is a self-report measure of major depressive disorder. The PHQ-9 scores each of the nine DSM-IV criteria for MDD from "0" (not at all) to "3" (nearly every day), providing a 0-27 severity score of depression. The higher the total score the more severe the depression. The change in the PHQ-9 total score between before the 12 week intervention and after the intervention is measured. The change score of MEL-T01 group is compared with the change score in the MEL-S01 group.

Outcome measures

Outcome measures
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=96 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
PHQ-9 Total Change From Baseline to Posttreatment: Experimental Group vs. Active Comparator Group
-1.941 adjusted score change
Interval -2.288 to -1.594
-1.429 adjusted score change
Interval -1.781 to -1.076

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12; TAU participants were pooled as all received identical treatment during this period, regardless of later allocation.

The quick inventory of depressive symptomatology (QIDS-SR16) is a self-report measure comprising of 16 questions on a scale of 0-3 which assess the severity of depressive symptoms. The inventory provides a total score between 0 and 48: the higher the total score the more severe the depression. For each of the three study arms, the change in total QIDS-SR16 scores between before the intervention and after the 12 week intervention is measured. Then, the average change scores in each of the three groups are compared with each other.

Outcome measures

Outcome measures
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=96 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
n=288 Participants
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
QIDS Total Change From Baseline to Posttreatment
-1.810 adjusted score change
Interval -2.075 to -1.545
-1.286 adjusted score change
Interval -1.555 to -1.017
-0.688 adjusted score change
Interval -0.843 to -0.533

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12; TAU participants were pooled as all received identical treatment during this period, regardless of later allocation.

Ruminative Response Scale (RRS), short version, is an eight item self-report questionnaire that uses a four point Likert-scale. This leads to a total score between 8 and 64 where higher values indicate higher depressive brooding. For each of the three study arms, the change in total RRS scores between before the intervention compared and after the 12 week intervention are measured. Then, the average change scores in each of the three groups are compared with each other.

Outcome measures

Outcome measures
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=96 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
n=288 Participants
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
RRS (Short Version) Total Change From Baseline to Posttreatment
-1.073 adjusted score change
Interval -1.352 to -0.795
-0.671 adjusted score change
Interval -0.954 to -0.388
-0.904 adjusted score change
Interval -1.067 to -0.741

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12; TAU participants were pooled as all received identical treatment during this period, regardless of later allocation.

The general anxiety disorder scale (GAD-7) is a seven-item self-report questionnaire that uses a 4-point scale (between 0 and 3) to evaluate the degree of anxiety symptoms. The questionnaire provides a total between 0 and 21: the higher the total score, the more severe the anxiety. For each of the three study arms, the change in total GAD-7 scores between before the intervention and after the 12 week intervention is measured. Then, the average change scores in each of the three groups are compared with each other.

Outcome measures

Outcome measures
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=96 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
n=288 Participants
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
GAD-7 Total Change From Baseline to Posttreatment
-1.168 adjusted score change
Interval -1.499 to -0.836
-0.706 adjusted score change
Interval -1.043 to -0.369
-0.335 adjusted score change
Interval -0.53 to -0.141

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12; TAU participants were pooled as all received identical treatment during this period, regardless of later allocation.

The Sheehan disability scale (SDS) is a self-administered three item questionnaire using a 11-point scale (between 0 and 10). The scale is used to measure functional impairment. The scale provides a total score between 0 and 30: the higher the score, the higher the functional impairment. In addition, the scale measures "the number of days lost to symptoms" and "the number of days unproductive due to the symptoms". For each of the three study arms, the change in total SDS scores between before the intervention and after the 12 week intervention is measured. Then, the average change scores in each of the three groups are compared with each other.

Outcome measures

Outcome measures
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=96 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
n=288 Participants
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
SDS Total Change From Baseline to Posttreatment
-1.663 adjusted score change
Interval -2.151 to -1.175
-1.041 adjusted score change
Interval -1.536 to -0.545
-0.272 adjusted score change
Interval -0.557 to 0.014

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12; TAU participants were pooled as all received identical treatment during this period, regardless of later allocation.

The positive valence systems scale (PVSS) is a 21-item self-report questionnaire using a scale from 1 to 9. This leads to a total score between 21 and 189 where a lower total score indicates higher anhedonia. For each of the three study arms, the change in total PVSS scores between before the intervention and after the 12 week intervention is measured. Then, the average change scores in each of the three groups are compared with each other.

Outcome measures

Outcome measures
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=96 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
n=288 Participants
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
PVSS Total Change From Baseline to Posttreatment
6.524 adjusted score change
Interval 4.553 to 8.494
6.952 adjusted score change
Interval 4.955 to 8.95
-0.426 adjusted score change
Interval -1.578 to 0.726

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12; TAU participants were pooled as all received identical treatment during this period, regardless of later allocation.

The well-being index (WHO-5) is a five item self-report questionnaire using a scale from 0 to 5. This leads to a total score is between 0 and 25: higher scores indicate higher subjective well-being. For each of the three study arms, the change in total WHO-5 scores between before the intervention and after the 12 week intervention is measured. Then, the average change scores in each of the three groups are compared with each other.

Outcome measures

Outcome measures
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=96 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
n=288 Participants
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
WHO-5 Total Change From Baseline to Posttreatment
1.148 adjusted score change
Interval 0.903 to 1.392
1.203 adjusted score change
Interval 0.955 to 1.452
0.156 adjusted score change
Interval 0.013 to 0.299

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Intention-to-treat cohort.

The patient health questionnaire (PHQ-9, Kroenke et al., 2001) is a self-report measure of major depressive disorder. The PHQ-9 scores each of the nine DSM-IV criteria for MDD from "0" (not at all) to "3" (nearly every day), providing a 0-27 severity score of depression. The higher the total score the more severe the depression. For the treatment MEL-T01 group, the change scores in the total PHQ-9 score between before the intervention and after the 12 week intervention is measured. Then, the correlation between the change score and the minutes played during the intervention is calculated. This leads to a correlation score that evaluates whether a higher symptom change is associated with higher playing time.

Outcome measures

Outcome measures
Measure
MEL-T01
n=337 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
Correlation Between PHQ-9 Total Change and Playing Time in Group MEL-T01
-0.126 fixed effect coefficient
Interval -0.508 to 0.76

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Intention-to-treat cohort.

The patient health questionnaire (PHQ-9, Kroenke et al., 2001) is a self-report measure of major depressive disorder. The PHQ-9 scores each of the nine DSM-IV criteria for MDD from "0" (not at all) to "3" (nearly every day), providing a 0-27 severity score of depression. The higher the total score the more severe the depression. For the active comparator MEL-S01 group, the change scores in the total PHQ-9 score between before the intervention and after the 12 week intervention is measured. Then, the correlation between the change score and the minutes played during the intervention is calculated. This leads to a correlation score that evaluates whether a higher symptom change is associated with higher playing time.

Outcome measures

Outcome measures
Measure
MEL-T01
n=347 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
Correlation Between PHQ-9 Total Change and Playing Time in Group MEL-S01
-0.300 fixed effect coefficient
Interval -0.907 to 0.307

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Intention-to-treat cohort.

The immersive experiences questionnaire (IEQ, Jennett et al., 2008) is a self-report questionnaire that measures the subjective experience of being immersed while playing a video game. It has 31 questions on a scale of 1-7. This creates a total score between 31 and 217: the higher totals indicate higher immersion. In addition, there is one question - "How immersed did you feel?" - on a scale of 1-10. For the treatment MEL-T01 group, we measure the correlation between 1) the change in the total PHQ-9 score between before the intervention and after the 12 week intervention and 2) the total IEQ score (excluding the one additional questionnaire) as measured after the 12 week intervention. This leads to a correlation score that evaluates whether a higher symptom change is associated with higher immersion in the game.

Outcome measures

Outcome measures
Measure
MEL-T01
n=337 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
Correlation Between PHQ-9 Total Change and IEQ in Group MEL-T01
-0.680 fixed effect coefficient
Interval -1.338 to -0.022

SECONDARY outcome

Timeframe: Day 0 to Day 84

Population: Intention-to-treat cohort.

The immersive experiences questionnaire (IEQ, Jennett et al., 2008) is a self-report questionnaire that measures the subjective experience of being immersed while playing a video game. It has 31 questions on a scale of 1-7. This creates a total score between 31 and 217: the higher totals indicate higher immersion. In addition, there is one question - "How immersed did you feel?" - on a scale of 1-10. For the treatment MEL-S01 group, we measure the correlation between 1) the change in the total PHQ-9 score between before the intervention and after the 12 week intervention and 2) the total IEQ score (excluding the one additional questionnaire) as measured after the 12 week intervention. This leads to a correlation score that evaluates whether a higher symptom change is associated with higher immersion in the game.

Outcome measures

Outcome measures
Measure
MEL-T01
n=347 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
Correlation Between PHQ-9 Total Change and IEQ in Group MEL-S01
-0.705 fixed effect coefficient
Interval -1.348 to -0.062

OTHER_PRE_SPECIFIED outcome

Timeframe: Day 0 to Day 84

Population: Per protocol completer cohort. Analyses were restricted to weeks 0-12; TAU participants were pooled as all received identical treatment during this period, regardless of later allocation.

The game addiction scale (GAS, Lemmens et al., 2009) is a self-report 7-item questionnaire using a 1-5 scale which measures game addiction. This provides a total between 7 and 35: the higher the scores indicate higher addiction. For each of the three study arms, the change in total GAS scores between before the intervention and after the 12 week intervention is measured. Then, the average change scores in each of the three groups are compared with each other.

Outcome measures

Outcome measures
Measure
MEL-T01
n=99 Participants
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=96 Participants
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual)
n=288 Participants
Treatment As Usual in healthcare for 12 weeks. This group combines both "First TAU, then MEL-T01" and "First TAU, then MEL-S01".
GAS Total Change From Baseline to Posttreatment
-0.485 adjusted score change
Interval -0.611 to -0.358
-0.227 adjusted score change
Interval -0.355 to -0.098
-0.363 adjusted score change
Interval -0.438 to -0.289

Adverse Events

MEL-T01

Serious events: 0 serious events
Other events: 52 other events
Deaths: 0 deaths

MEL-S01

Serious events: 0 serious events
Other events: 55 other events
Deaths: 0 deaths

TAU (Treatment-As-Usual; First TAU, Then MEL-T01)

Serious events: 0 serious events
Other events: 16 other events
Deaths: 0 deaths

TAU (Treatment-As-Usual; First TAU, Then MEL-S01)

Serious events: 0 serious events
Other events: 24 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
MEL-T01
n=337 participants at risk
MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects. MEL-T01: A 12 week intervention with MEL-T01.
MEL-S01
n=347 participants at risk
MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements. MEL-S01: A 12 week intervention with MEL-S01.
TAU (Treatment-As-Usual; First TAU, Then MEL-T01)
n=153 participants at risk
Treatment-as-usual in healthcare for 12 weeks. Then, the participant is given acess to MEL-T01 for 12 weeks.
TAU (Treatment-As-Usual; First TAU, Then MEL-S01)
n=164 participants at risk
Treatment-as-usual in healthcare for 12 weeks. Then, the participant is given acess to MEL-S01 for 12 weeks.
Psychiatric disorders
Anxiety
2.4%
8/337 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
3.2%
11/347 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
2.6%
4/153 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
3.0%
5/164 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
General disorders
Nausea
1.5%
5/337 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
2.6%
9/347 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
1.3%
2/153 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
3.0%
5/164 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
Product Issues
Frustration
8.6%
29/337 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
9.5%
33/347 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
7.2%
11/153 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
7.3%
12/164 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
Product Issues
Stress
3.3%
11/337 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
3.7%
13/347 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
2.0%
3/153 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
3.7%
6/164 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
General disorders
Headache
0.89%
3/337 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.29%
1/347 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.65%
1/153 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.61%
1/164 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
General disorders
Arm and neck pain
0.89%
3/337 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.58%
2/347 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.00%
0/153 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.00%
0/164 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
Psychiatric disorders
PTSD exacerbates
0.30%
1/337 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.29%
1/347 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.00%
0/153 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.61%
1/164 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
Product Issues
Audiovisual discomfort
0.00%
0/337 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.58%
2/347 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.65%
1/153 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.00%
0/164 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
Psychiatric disorders
Nightmares
0.30%
1/337 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.00%
0/347 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.00%
0/153 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.
0.00%
0/164 • The adverse event data was collected during the weeks 0-24.
Patients could self-report Adverse Events using a open-ended repeatedly prompted within-intervention questionnaire, a Jira questionnaire available in intervention main menu, email, and phone calls to clinical subject coordinators.

Additional Information

Prof. J. Matias Palva

Aalto University

Phone: +358401547779

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place